Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis c-related cirrhosis

被引:150
作者
Pekow, Joel R.
Han, Atul K.
Zheng, Hui
Chung, Raymond T.
机构
[1] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA
关键词
hepatitis C virus; hepatocellular carcinoma; hepatc steatosis; cirrhosis;
D O I
10.1002/cncr.22701
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Chronic hepatitis C can result in fatty changes in the liver. Previous studies have suggested that hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus (HCV) infection. The authors sought to determine whether hepatic steatosis is associated with hepatocellular carcinoma (HCC) in a cohort of patients with hepatitis C-related cirrhosis. METHODS. The authors retrospectively identified 94 consecutive patients with hepatitis C cirrhosis who underwent liver transplantation from 1992 to 2005 and had pathology available for review. Of these, 32 had evidence of HCC, and 62 had no HCC on explant histology. All explant specimens were graded again for steatosis bV a single, blinded pathologist. Steatosis, age, sex, body mass index, HCV RNA, HCV genotype, Model for End-Stage Liver Disease (MELD) score, chronic alcohol use, and diabetes were examined in univariate and multivariate analyses for association with HCC. RESULTS. In total, 69% of patients in the HCC group and 50% of patients in the control group had evidence of steatosis (1+) on histology. Odds ratios for the development of HCC for each grade of steatosis compared with grade 0 were as follows: grade 1 (1.61 [0.6-4.3]), grade 2 (3.68 (1.1-12.8]), and grade 3 or 4 (8.02 [0.6-108.31) (P =.03 for the trend). In univariate analysis, there was a significant association between increasing steatosis grade (P =.03), older age (56 years vs 49 years; P <.02), higher aspartate aminotransferase (122.5 U/L vs 91.5 U/L; P =.005), higher alanine amino transferase (95.8 U/L vs 57.2 U/L; P =.002), higher alpha- feto protein (113.5 ng/mL vs 17.8 ng/mL; P <.001), lower median HCV RNA (239,000 IU/mL vs 496,500 IU/mL; P =.02), higher biologic MELD score (21.8 vs 20.3; P =.03), and risk of HCC. In multivariate analysis, age (P =.02), AFP (P.007), and steatosis (P =.045) were significantly associated with HCC. CONCLUSIONS. in patients with HCV-related cirrhosis, the presence of hepatic steatosis is independently associated with the development of hepatocellular carcinoma. These findings suggest that steatosis poses an additional risk for HCC and that increased vigilance should be practiced in surveillance of persons with both HCV and steatosis.
引用
收藏
页码:2490 / 2496
页数:7
相关论文
共 50 条
  • [21] Hepatocellular carcinoma in patients cured of chronic hepatitis C: Minimal steatosis
    Rocha, Chiara
    Doyle, Erin H.
    Bowman, Chip A.
    Fiel, M-Isabel
    Stueck, Ashley E.
    Goossens, Nicolas
    Bichoupan, Kian
    Crismale, James F.
    Makkar, Jasnit
    Lewis, Sara
    Perumalswami, Ponni V.
    Schiano, Thomas D.
    Hoshida, Yujin
    Schwartz, Myron
    Branch, Andrea D.
    Patel, Neal
    CANCER MEDICINE, 2023, 12 (09): : 10175 - 10186
  • [22] Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals
    Thomas F. Baumert
    Frank Jühling
    Atsushi Ono
    Yujin Hoshida
    BMC Medicine, 15
  • [23] De Novo Hepatocellular Carcinoma in Hepatitis C-Related Cirrhosis: Are Advanced Glycation End Products a Key Driver?
    Abdel-Razik, Ahmed
    Shabana, Walaa
    El Nakib, Ahmed Mohamed
    Abdelsalam, Mostafa
    Abdelwahab, Ahmed
    Hasan, Ahmad S.
    Elzehery, Rasha
    Elhelaly, Rania
    Fathy, Aya Ahmed
    Mostafa, Sally Abdallah
    El-Wakeel, Niveen
    Moemen, Dalia
    Eldars, Waleed
    Yassen, Ahmed H.
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2021, 11
  • [24] Antiviral Therapy in Patients after Treatment for Hepatitis C-Related Hepatocellular Carcinoma
    Shin, Su Rin
    Paik, Seung Woon
    Gwak, Geum-Youn
    Choi, Moon Seok
    Lee, Joon Hyoek
    Koh, Kwang Cheol
    Yoo, Byung Chul
    GUT AND LIVER, 2011, 5 (01) : 77 - 81
  • [25] Effects of interferon therapy on development of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis: A meta-analysis of randomized controlled trials
    Qu, Li-Shuai
    Chen, Hong
    Kuai, Xiao-Ling
    Xu, Zheng-Fu
    Jin, Fei
    Zhou, Guo-Xiong
    HEPATOLOGY RESEARCH, 2012, 42 (08) : 782 - 789
  • [26] Antiviral Therapy in Patients With Chronic Hepatitis C-related Hepatocellular Carcinoma Responding to Palliative Treatment
    Yu, Jung-Hwan
    Kim, Ja Kyung
    Lee, Kwan Sik
    Lee, Jung Il
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2018, 52 (06) : 557 - 562
  • [27] Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection
    Ohata, K
    Hamasaki, K
    Toriyama, K
    Matsumoto, K
    Saeki, A
    Yanagi, K
    Abiru, S
    Nakagawa, Y
    Shigeno, M
    Miyazoe, S
    Ichikawa, T
    Ishikawa, H
    Nakao, K
    Eguchi, K
    CANCER, 2003, 97 (12) : 3036 - 3043
  • [28] Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality
    Toshikuni, Nobuyuki
    Arisawa, Tomiyasu
    Tsutsumi, Mikihiro
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (11) : 2876 - 2887
  • [29] A patient with hepatitis C-related liver cirrhosis and hepatocellular carcinoma who was cured with an orthotopic liver transplantation and interferon therapy
    Shibata, M
    Yanaga, K
    Morizane, T
    Yanagawa, T
    Hirakawa, M
    Ueno, Y
    Esquivel, CO
    Mitamura, K
    JOURNAL OF GASTROENTEROLOGY, 2003, 38 (06) : 598 - 602
  • [30] Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma
    Li-Ping Chen
    Jun Zhao
    Yan Du
    Yi-Fang Han
    Tong Su
    Hong-Wei Zhang
    Guang-Wen Cao
    World Journal of Virology, 2012, 1 (06) : 174 - 183